Research Area
Product Type
United States ( Change Country )
Enzastaurin (LY317615) Chemical Structure
Recommended Products
Chelerythrine Chloride
Chelerythrine is a potent, selective, and cell-permeable PKC inhibitor (IC50 = 660 nM).
Zoledronic Acid (Zoledronate)
A potent nitrogen-containing bisphosphonates.It inhibited proliferation of human foetal osteoblastic cell line (hFOB) with an IC50 of 40 μM.
CX-4945
CX-4945 is a potent and selective ATP-competitive small molecule protein kinase CK2 inhibitor with a Ki and an IC50 of 0.38 and 1 nM for recombinant human CK2α, respectively.
Fingolimod (FTY720)
Fingolimod (FTY720) Gilenia is Src-bcr-Abl Inhibitor & S1P receptor agonist with IC50 of 0.137, 10.98 nM for (S)- and (R)- FTY720-phosphate.
Chelerythrine Chloride
Chelerythrine is a potent, selective, and cell-permeable PKC inhibitor (IC50 = 660 nM).
Zoledronic Acid (Zoledronate)
A potent nitrogen-containing bisphosphonates.It inhibited proliferation of human foetal osteoblastic cell line (hFOB) with an IC50 of 40 μM.
Staurosporine
Staurosporine is a prototypical potent ATP-competitive kinase inhibitor with IC50 of 0.7, 7, 8.5, 6, 20 nM for PKC, PKA,PKG, p60v-src tyrosine protein kinase, CaM kinase II, respectively.
Theophylline(Theo-Dur)
Theophylline (Theo-Dur) is a methylxanthine agent and has bronchodilator properties and is used in the treatment of asthma and COAD.
CX-4945
CX-4945 is a potent and selective ATP-competitive small molecule protein kinase CK2 inhibitor with a Ki and an IC50 of 0.38 and 1 nM for recombinant human CK2α, respectively.
LY2157299
LY2157299 is a novel selective small molecule transforming growth factor beta receptor (TGF-βR) kinase inhibitor with IC50 of 86 nM and 2 nM for TβR1 and 2 nM, respectively.
Biological Activity
| Information | Enzastaurin (LY317615) is a potent PKC beta inhibitor for PKCβ, PKCα, PKCγ and PKCε with IC50 of 6 nM, 39 nM, 83 nM and 110 nM, respectively. | |||||
|---|---|---|---|---|---|---|
| Targets | PKCβ | PKCα | PKCγ | PKCε | ||
| IC50 | 6 nM [1] | 39 nM [1] | 83 nM [1] | 110 nM [1] | ||
| In vitro | Enzastaurin application results in a marked dose-dependent inhibition of growth in all MM cell lines investigated, including MM.1S, MM.1R, RPMI 8226 (RPMI), RPMI-Dox40 (Dox40), NCI-H929, KMS-11, OPM-2, and U266, with IC50 values ranging from 0.6 to 1.6 μM. Enzastaurin direct impacts human tumor cells, inducing apoptosis and suppressing proliferation in cultured tumor cells. Enzastaurin also suppresses the phosphorylation of GSK3βser9, ribosomal protein S6S240/244, and AKTThr308 while having no direct effect on VEGFR phosphorylation. [1] Enzastaurin increases apoptosis in malignant lymphocytes of CTCL. When combined with GSK3 inhibitors, enzastaurin demonstrated an enhancement of cytotoxicity levels. Treatment with a combination of enzastaurin and the GSK3 inhibitor AR-A014418 led to increased levels of β-catenin total protein and β-catenin-mediated transcription. Blocking of β-catenin-mediated transcription or small hairpin RNA (shRNA) knockdown of β-catenin induced the same cytotoxic effects as that of enzastaurin plus AR-A014418. Additionally, treatment with enzastaurin and AR-A014418 decreased the mRNA levels and surface expression of CD44. [2] | |||||
| In vivo | Treatment of xenografts with Enzastaurin and radiation produced greater reductions in density of microvessels than either treatment alone. The decrease in microvessel density corresponded to delayed tumor growth. [3] | |||||
| Clinical Trials | Phase II clinical trials of enzastaurin for the treatment of neoplasms have been completed. | |||||
| Features | ||||||
Protocol
Kinase Assay: [1]
| Kinase inhibition assays | The inhibition of PKCβII, PKCα, PKCε, or PKCγ activity by enzastaurin is determined using a filter plate assay format measuring 33P incorporation into myelin basic protein substrate. Reactions are done in 100 μL reaction volumes in 96-well polystyrene plates with final conditions as follows: 90 mM HEPES (pH 7.5), 0.001% Triton X-100, 4% DMSO, 5 mM MgCl2, 100 μM CaCl2, 0.1 mg/mL phosphatidylserine, 5 μg/mL diacetyl glyerol, 30 μM ATP, 0.005 μCi/μL 33ATP, 0.25 mg/mL myelin basic protein, serial dilutions of enzastaurin (1-2,000 nM), and recombinant human PKCβII, PKCα, PKCε, or PKCγ enzymes (390, 169, 719, or 128 pM, respectively). Reactions are started by addition of the enzyme and incubated at room temperature for 60 minutes. They are then quenched with 10% H3PO4, transferred to multiscreen anionic phosphocellulose 96-well filter plates, incubated for 30 to 90 minutes, filtered and washed with 4 volumes of 0.5% H3PO4 on a vacuum manifold. Scintillation cocktail was added and plates are read on a Microbeta scintillation counter. IC50 values were determined by fitting a three-variable logistic equation to the 10-point dose-response data using ActivityBase 4.0. |
|---|
Cell Assay: [1]
| Cell lines: | HCT116 and U87MG cells |
|---|---|
| Concentrations: | 0.3 - 4 μM |
| Incubation Time: | 72 hours |
| Method: | Induction of apoptosis by enzastaurin was measured by nucleosomal fragmentation and terminal deoxynucleotidyl transferase-mediated nick-end labeling (TUNEL) and staining in HCT116 and U87MG cell lines. Briefly, 5 × 103 cells are plated per well in 96-well plates (1% FBS-supplemented media conditions), incubated with or without Enzastaurin for 48 to 72 hours. The absorbance values are normalized to those from control-treated cells to derive a nucleosomal enrichment factor at all concentrations as per the manufacturer's protocol. The concentrations studied ranges from 0.1 to 10 μM. In situ TUNEL staining is assayed with the In situ Cell Death Detection, Fluorescein kit. Cells (7.5 × 104) are plated per well in 6-well plates and incubated 72 hours in 1% FBS-supplemented media ± Enzastaurin. Fluorescein-labeled DNA strand breaks are detected with the BD epics flow cytometer. Ten thousand, single-cell, FITC-staining events are collected for each test. |
Animal Study:[1]
| Animal Models: | Athymic nude mice |
|---|---|
| Formulation: | 10% acacia in water |
| Dosages: | 75 mg/kg twice daily |
| Administration: | By gavage |
Chemical Information
| Molecular Weight (WM): | 515.61 |
|---|---|
| Formula: | C32H29N5O2 |
| CAS No.: | 170364-57-5 |
| Synonyms: |
N/A
|
| Dissolve in (25°C): | DMSO ≥50mg/mL |
| Water <1mg/mL | |
| Ethanol <1mg/mL | |
| Storage: | 2 years-20°CPowder |
| 1 week-4°Cin DMSO | |
| 1 month-80°in DMSO |
Quality Control & MSDS
Research Area
Notes:
Related Inhibitors
Recommended Screening Libraries
Chemical Library
A collection of 864 bioactive compounds
Inhibitor Library
A collection of 481 inhibitors
Kinase Inhibitor Library
A collection of 194 kinase inhibitors
Tyrosine Kinase Inhibitor Library
A collection of 85 tyrosine kinase inhibitors.
FDA Approved Drug Library
A collection of 426 FDA approved drugs
Natural Product Library
A collection of 139 natural products
Chemotherapeutic Agent Library
A collection of 40 chemotherapeutic agents
Epigenetics Compound library
A unique collection of 17 small molecule modulators
Stem Cell Compound library
A unique collection of 47 small molecule inhibitors
GPCR Compound library
A unique collection of 63 GPCR small molecules
Keywords:buy Enzastaurin (LY317615) | Enzastaurin (LY317615) supplier | purchase Enzastaurin (LY317615) | Enzastaurin (LY317615) cost | Enzastaurin (LY317615) manufacturer | order Enzastaurin (LY317615) | Enzastaurin (LY317615) distributor